<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00736853</url>
  </required_header>
  <id_info>
    <org_study_id>CR015112</org_study_id>
    <secondary_id>JNS013-JPN-04</secondary_id>
    <nct_id>NCT00736853</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of Acetaminophen Plus Tramadol Hydrochloride (JNS013) in Participants With Chronic Pain</brief_title>
  <official_title>A Phase 3 Study of JNS013 in Patients With Chronic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Pharmaceutical K.K.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Pharmaceutical K.K.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of tramadol hydrochloride
      plus acetaminophen (JNS013) in participants with chronic pain accompanied by osteoarthritis
      (a progressive and degenerative joint disease, in which the joints become painful and stiff)
      of the knee or low back pain (acute or chronic pain in the lumbar or sacral regions) which
      cannot be controlled sufficiently with non-steriodal anti-inflammatory drugs (NSAIDs).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center (when more than one hospital or medical school team work on a medical
      research study), double-blind (test or experiment in which neither the person giving the
      treatment nor the participant knows which treatment the participant is receiving),
      placebo-controlled (an inactive substance; a pretend treatment [with no drug in it] that is
      compared in a clinical trial with a drug to test if the drug has a real effect), parallel
      group comparison study. The total duration of the study will be 11 weeks and consists of 4
      periods; a pre-observation period (4 weeks), open-label period (2 weeks), double-blind period
      (4 weeks) and follow-up period (1 week). Participants will receive tramadol hydrochloride
      plus acetaminophen tablets orally 4 times daily for 2 weeks with no less than 4-hour
      intervals (up to 8 tablets per day) during the open-label period and the dose will be fixed
      for each participant in the latter 1 week. During the double-period participants will receive
      tramadol hydrochloride plus acetaminophen tablets or placebo at the same dose as used for the
      latter 1 week of the open-label period for up to 4 weeks. Efficacy will be primarily
      evaluated by number of participants with insufficient pain relief after the start of
      double-blind period. Participant's safety will be monitored throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Insufficient Pain Relief After the Start of Double-Blind Period</measure>
    <time_frame>Day 28 of double-blind period</time_frame>
    <description>The pain relief was regarded as insufficient, if either of the following was met, a) the value of average pain intensity felt in daily living during the past 24 hours (Visual analog scale 24 [VAS24] ) on 2 consecutive days in double-blind period worsened greater than 15 millimeter (mm) compared with the average VAS24 during 3 days before the end of open-label period, b) when the participant asked for discontinuation of treatment with the study drug because of insufficient pain relief.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Visual Analog Scale for the Last 24 Hours (VAS24) Value at the Start of the Double-Blind Period From the Baseline Value at the Start of the Open-Label Period</measure>
    <time_frame>Day 1 of open-label period and Day 1 of double-blind period</time_frame>
    <description>Pain over the last 24 hours was assessed by using VAS score ranges from 0 mm=no pain to 100 mm=worst possible pain. An increase in score from Baseline represented disease progression and decrease represented improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the VAS24 Value From the Baseline at the Final Time Point of the Double-Blind Period</measure>
    <time_frame>Day 1 and Day 28 of double-blind period</time_frame>
    <description>Pain over the last 24 hours was assessed by using VAS score ranges from 0 mm=no pain to 100 mm=worst possible pain. An increase in score from Baseline represented disease progression and decrease represented improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pain Intensity (PI) Score During Open-Label Period</measure>
    <time_frame>Pre-dose and post-dose at 2 hours, 4 hours on Day 1, and Day 8 of open-label period</time_frame>
    <description>PI was evaluated on a 4-stage scale with a score ranging from 0 to 3, wherein 0=no pain and 3=severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean PI Score During Double-Blind Period</measure>
    <time_frame>Pre-dose and post-dose at 2 hours, 4 hours on Day 1, 8, 15, 22 and 28 of double-blind period</time_frame>
    <description>The PI was evaluated on a 4-stage scale with a score ranging from 0 to 3, wherein 0=no pain and 3=severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pain Intensity Difference (PID) During the Open-Label Period</measure>
    <time_frame>Pre-dose, and post-dose at 2 hours, 4 hours on Day 1, and Day 8 of open-label period</time_frame>
    <description>The PID was calculated as PI at pre-dose on Day 1, 8 minus PI at post-dose time point (i.e., 2 hours and 4 hours) on Day 1, 8 respectively. Baseline PI score ranges from 1=minor to 3=severe, post-baseline PI score ranges from 0=none to 3=severe. Total possible score range for PID: -2=worst to 3=best.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean PID During the Double-Blind Period</measure>
    <time_frame>Pre-dose, and post-dose at 2 hours, 4 hours on Day 1, 8, 15, 22 and 28 of double-blind period</time_frame>
    <description>The PID was calculated as PI at pre-dose on Day 1, 8, 15, 22, 28 minus PI at post-dose time point (i.e., 2 hours and 4 hours) on Day 1, 8, 15, 22, 28 respectively. Baseline PI score ranges from 1=minor to 3=severe, post-baseline PI score ranges from 0=none to 3=severe. Total possible score range for PID: -2=worst to 3=best.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pain Relief (PAR) Score During the Open-Label Period</measure>
    <time_frame>2 hours, 4 hours post-dose on Day 1, and Day 8 of open-label period</time_frame>
    <description>PAR was evaluated based on 5-stage scale with a score ranging from 0 to 4, wherein, 0=no relief and 4=complete relief.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean PAR Score During the Double-Blind Period</measure>
    <time_frame>2 hours, 4 hours post-dose on Day 1, 8, 15, 22 and 28 of double-blind period</time_frame>
    <description>PAR was evaluated based on 5-stage scale with a score ranging from 0 to 4, wherein, 0=no relief and 4=complete relief.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Difference and Pain Relief Scores (PRID) During the Open-Label Period</measure>
    <time_frame>2 hours, 4 hours post-dose on Day 1, and Day 8 of open-label period</time_frame>
    <description>The PRID is defined as sum of PID and PAR Scores for each participant at each evaluation time point (at 2 and 4 hours after the dosing). The overall possible score ranges for PRID is -2=worst to 7=best. The PID was calculated as PI at pre-dose on Day 1, 8 minus PI at post-dose time point (i.e., 2 hours and 4 hours) on Day 1, 8 respectively. Baseline PI score ranges from 1=minor to 3=severe, post-baseline PI score ranges from 0=none to 3=severe. Total possible score range for PID: -2=worst to 3=best and PAR was evaluated based on a 5-stage scale score ranges from 0=no relief and 4=complete relief.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Difference and Pain Relief Scores (PRID) During the Double-Blind Period</measure>
    <time_frame>2 hours, 4 hours post-dose on Day 1, 8, 15, 22 and 28 of double-blind period</time_frame>
    <description>The PRID is defined as sum of PID and PAR Scores for each participant at each evaluation time point (at 2 and 4 hours after the dosing). The overall possible score range for PRID is -2=worst to 7=best. The PID was calculated as PI at pre-dose on Day 1, 8, 15, 22, 28 minus PI at post-dose time point (i.e., 2 hours and 4 hours) on Day 1, 8, 15, 22, 28 respectively. Baseline PI score ranges from 1=minor to 3=severe, post-baseline PI score ranges from 0=none to 3=severe. Total possible score range for PID: -2=worst to 3=best and PAR was evaluated based on a 5-stage scale score ranges from 0=no relief and 4=complete relief.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum of Pain Intensity Difference (SPID) Score During the Open-Label Period</measure>
    <time_frame>Day 1, and Day 8 of open-label period</time_frame>
    <description>The SPID is defined as sum of the PID at 2 and 4 hours after dosing on each evaluation day. The overall possible score ranges for SPID is -4=worst to 6=best. The PID was calculated as PI at pre-dose on Day 1, 8 minus PI at post-dose time point (i.e., 2 hours and 4 hours) on Day 1, 8 respectively. Baseline PI score ranges from 1=minor to 3=severe, post-baseline PI score ranges from 0=none to 3=severe. Total possible score range for PID: -2=worst to 3=best.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum of Pain Intensity Difference (SPID) Score During the Double-Blind Period</measure>
    <time_frame>Day 1, 8, 15, 22 and 28 of double-blind period</time_frame>
    <description>The SPID is defined as sum of the PID at 2 and 4 hours after dosing on each evaluation day. The overall possible score ranges for SPID is -4=worst to 6=best. The PID was calculated as PI at pre-dose on Day 1, 8, 15, 22, 28 minus PI at post-dose time point (i.e., 2 hours and 4 hours) on Day 1, 8, 15, 22, 28 respectively. Baseline PI score ranges from 1=minor to 3=severe, post-baseline PI score ranges from 0=none to 3=severe. Total possible score range for PID: -2=worst to 3=best.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Pain Relief (TOTPAR) Score During the Open-Label Period</measure>
    <time_frame>Day 1 and Day 8 of open-label period</time_frame>
    <description>The TOTPAR is defined as sum of PAR at 2 hours after dosing and the PAR at 4 hours after dosing on each evaluation day. Pain relief as evaluated on 5-stage scale with a score ranging from 0=no relief and 4=complete relief. Total possible score range for TOTPAR is 0=no relief to 8=complete relief.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Pain Relief (TOTPAR) Score During the Double-Blind Period</measure>
    <time_frame>Day 1, 8, 15, 22 and 28 of double-blind period</time_frame>
    <description>The TOTPAR is defined as sum of PAR at 2 hours after dosing and the PAR at 4 hours after dosing on each evaluation day. Pain relief as evaluated on 5-stage scale with a score ranging from 0=no relief and 4=complete relief. Total possible score range for TOTPAR is 0=no relief to 8=complete relief.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum of Pain Relief Combined With Pain Intensity Difference (SPRID) Score During the Open-Label Period</measure>
    <time_frame>Day 1, and Day 8 of open-label period</time_frame>
    <description>The SPRID is defined as sum of PID and PAR Scores at 2 hours and 4 hours after the dosing on each evaluation day. The overall possible score ranges for SPRID is -4=worst to 14=best. The PID was calculated as PI at pre-dose on Day 1, 8 minus PI at post-dose time point (i.e., 2 hours and 4 hours) on Day 1, 8 respectively. Baseline PI score ranges from 1=minor to 3=severe, post-baseline PI score ranges from 0=none to 3=severe. Total possible score range for PID: -2=worst to 3=best and PAR was evaluated based on 5-stage scale with a score ranging from 0=no relief to 4=complete relief.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum of Pain Relief Combined With Pain Intensity Difference (SPRID) Score During the Double-Blind Period</measure>
    <time_frame>Day 1, 8, 15, 22 and 28 of double-blind period</time_frame>
    <description>The SPRID is defined as sum of PID and PAR Scores at 2 hours and 4 hours after the dosing on each evaluation day. The overall possible score ranges for SPRID is -4=worst to 14=best. The PID was calculated as PI at pre-dose on Day 1, 8, 15, 22, 28 minus PI at post-dose time point (i.e., 2 hours and 4 hours) on Day 1, 8, 15, 22, 28 respectively. Baseline PI score ranges from 1=minor to 3=severe, post-baseline PI score ranges from 0=none to 3=severe. Total possible score range for PID: -2=worst to 3=best and PAR was evaluated based on 5-stage scale with a score ranging from 0 to 4, wherein, 0=no relief and 4=complete relief.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Roland Morris Disability Questionnaire (RDQ) Total Score at Day 14 of Open-Label Period</measure>
    <time_frame>Day 1 and Day 14 of open-label period</time_frame>
    <description>The RDQ is self-administered measure of disability caused by low back pain and consists of 24 statements. The total score ranges from 0=no disability to 24=severe disability. The higher scores indicate greater physical disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in RDQ Total Score at Day 28 of Double-Blind Period</measure>
    <time_frame>Day 1 and Day 28 of double-blind period</time_frame>
    <description>The RDQ is self-administered measure of disability caused by low back pain and consists of 24 statements. The total score ranges from 0=no disability to 24=severe disability. The higher scores indicate greater physical disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Questionnaire Score at Day 14 of Open-Label Period</measure>
    <time_frame>Day 1 and Day 14 of open-label period</time_frame>
    <description>The WOMAC questionnaire is an activity of daily living (ADL) indicator for Knee Osteoarthritis and designed to capture the elements of pain, stiffness, extent of obstruction to daily activities (EODA) and general index. The score for each element ranges from 0=better ADL to 10=worse ADL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in WOMAC Questionnaire Score at Day 28 of Double-Blind Period</measure>
    <time_frame>Day 1 and Day 28 of double-blind period</time_frame>
    <description>The WOMAC questionnaire is an activity of daily living (ADL) indicator for knee osteoarthritis and designed to capture the elements of pain, stiffness, extent of obstruction to daily activities (EODA) and general index. The score for each element ranges from 0=better ADL to 10=worse ADL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short Form-36 (SF-36) Score at Day 14 of Open-Label Period</measure>
    <time_frame>Day 1 and Day 14 of open-label period</time_frame>
    <description>The SF-36 is a survey of participant health and quality of life. It consists of 8 sub-scales, which are the weighted sums of the questions in their section. The 8 sub-scales are: physical functioning, role-physical, role-emotional, general health, social functioning, bodily pain, vitality, mental health. Each item is scored on a scale ranging from 0-100. Higher score defines a more favorable health status or a better mental status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SF-36 at Day 28 of Double-Blind Period</measure>
    <time_frame>Day 1 and Day 28 of double-blind period</time_frame>
    <description>The SF-36 is a survey of participant health and quality of life. It consists of 8 sub-scales, which are the weighted sums of the questions in their section. The 8 sub-scales are: physical functioning, role-physical, role-emotional, general health, social functioning, bodily pain, vitality, mental health. Each item is scored on a scale ranging from 0-100. Higher score defines a more favorable health status or a better mental status.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">321</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Tramadol Hydrochloride Plus Acetaminophen (Open-Label)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tramadol Hydrochloride Plus Acetaminophen (Double Blind)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Double-Blind)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol Hydrochloride Plus Acetaminophen (Open-Label)</intervention_name>
    <description>Fixed dose combination of tramadol 37.5 milligram (mg)/acetaminophen 325 mg, 1 or 2 tablets 4 times daily will be given for one week; dose level will be fixed for each participant during the second week based on analgesic efficacy and tolerability (maximum daily dose will be 8 tablets).</description>
    <arm_group_label>Tramadol Hydrochloride Plus Acetaminophen (Open-Label)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol Hydrochloride Plus Acetaminophen (Double-Blind)</intervention_name>
    <description>Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose [number of tablets] as that for the second week in the open-label period) will be given 4 times daily up to 4 weeks.</description>
    <arm_group_label>Tramadol Hydrochloride Plus Acetaminophen (Double Blind)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Double-Blind)</intervention_name>
    <description>Matching placebo will be given up to 4 weeks.</description>
    <arm_group_label>Placebo (Double-Blind)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with sustention of chronic pain associated with OA or LBP for at least 3
             months

          -  Participants whose pain cannot be controlled sufficiently with at least 14-day
             continuous treatment with identical oral NSAIDs at a usual maximum dose during 3
             months prior to this study

          -  Outpatients

          -  Ambulatory participants without need for any supportive device or assistance during
             daily life

        Exclusion Criteria:

          -  Participants with conditions for which opioids are contraindicated

          -  Participants with conditions for which acetaminophen is contraindicated

          -  Participants with history of convulsion or the possibility of convulsive seizure

          -  Participants with concurrent, previous, or possible alcohol dependence, drug
             dependence, or narcotic addiction

          -  Pregnant participants or those who may be pregnant, lactating mothers, and
             participants who wish pregnancy during the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Pharmaceutical K.K. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Pharmaceutical K.K.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiba N/A</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edogawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iruma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kawasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumagaya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kurume</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Meguro</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minato</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Niigata N/A</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ohta-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Okazaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sagamihara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Setagaya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shibuya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjuku-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&amp;studyid=423&amp;filename=CR015112_CSR.pdf</url>
    <description>A Phase III Study of JNS013 in Patients with Chronic Pain</description>
  </link>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2008</study_first_submitted>
  <study_first_submitted_qc>August 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2008</study_first_posted>
  <results_first_submitted>April 12, 2013</results_first_submitted>
  <results_first_submitted_qc>July 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 26, 2013</results_first_posted>
  <last_update_submitted>July 22, 2013</last_update_submitted>
  <last_update_submitted_qc>July 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic pain</keyword>
  <keyword>Acetoaminophen</keyword>
  <keyword>Tramadol</keyword>
  <keyword>Osteoarthritis of the knee</keyword>
  <keyword>Low back pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tramadol Hydrochloride and Acetaminophen (Open-Label)</title>
          <description>Fixed dose combination of tramadol 37.5 milligram (mg)/acetaminophen 325 mg, 1 or 2 tablets 4 times daily was given for one week; dose level was fixed for each participant during the second week based on analgesic efficacy and tolerability (maximum daily dose was 8 tablets).</description>
        </group>
        <group group_id="P2">
          <title>Tramadol Hydrochloride and Acetaminophen (Double-Blind)</title>
          <description>Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose [number of tablets] as that for the second week in the open-label period) was given 4 times daily up to 4 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Placebo (Double-Blind)</title>
          <description>Matching placebo was given up to 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Open-Label Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="319"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="277"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="187"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Started but not treated</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to meet the transfer criteria</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to attend hospital appointments</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Double-Blind Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="94"/>
                <participants group_id="P3" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="48"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible to participate the study</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Fixed dose combination of tramadol 37.5 milligram (mg)/acetaminophen 325 mg, 1 or 2 tablets 4 times daily was given for one week; dose level was fixed for each participant during the second week based on analgesic efficacy and tolerability (maximum daily dose was 8 tablets) during the open-label period. Participants received placebo or fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg (same dose which was used in second week of open-label period) in double-blind period.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="277"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Efficacy analysis set: Participants who received at least 1 dose of study drug.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.0" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Efficacy analysis set: Participants who received at least 1 dose of study drug.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Insufficient Pain Relief After the Start of Double-Blind Period</title>
        <description>The pain relief was regarded as insufficient, if either of the following was met, a) the value of average pain intensity felt in daily living during the past 24 hours (Visual analog scale 24 [VAS24] ) on 2 consecutive days in double-blind period worsened greater than 15 millimeter (mm) compared with the average VAS24 during 3 days before the end of open-label period, b) when the participant asked for discontinuation of treatment with the study drug because of insufficient pain relief.</description>
        <time_frame>Day 28 of double-blind period</time_frame>
        <population>Efficacy analysis set included participants who received at least one dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride and Acetaminophen (Double-Blind)</title>
            <description>Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose [number of tablets] as that for the second week in the open-label period) was given 4 times daily up to 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Double-Blind)</title>
            <description>Matching placebo was given up to 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Insufficient Pain Relief After the Start of Double-Blind Period</title>
          <description>The pain relief was regarded as insufficient, if either of the following was met, a) the value of average pain intensity felt in daily living during the past 24 hours (Visual analog scale 24 [VAS24] ) on 2 consecutive days in double-blind period worsened greater than 15 millimeter (mm) compared with the average VAS24 during 3 days before the end of open-label period, b) when the participant asked for discontinuation of treatment with the study drug because of insufficient pain relief.</description>
          <population>Efficacy analysis set included participants who received at least one dose of the study drug.</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Log Rank</method>
            <method_desc>Stratified Log-rank test with the target disease as the stratification factor</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.377</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.221</ci_lower_limit>
            <ci_upper_limit>0.641</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Visual Analog Scale for the Last 24 Hours (VAS24) Value at the Start of the Double-Blind Period From the Baseline Value at the Start of the Open-Label Period</title>
        <description>Pain over the last 24 hours was assessed by using VAS score ranges from 0 mm=no pain to 100 mm=worst possible pain. An increase in score from Baseline represented disease progression and decrease represented improvement.</description>
        <time_frame>Day 1 of open-label period and Day 1 of double-blind period</time_frame>
        <population>Efficacy analysis set included participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride and Acetaminophen (Open-Label)</title>
            <description>Fixed dose combination of tramadol 37.5 milligram (mg)/acetaminophen 325 mg, 1 or 2 tablets 4 times daily was given for one week; dose level was fixed for each participant during the second week based on analgesic efficacy and tolerability (maximum daily dose was 8 tablets).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Visual Analog Scale for the Last 24 Hours (VAS24) Value at the Start of the Double-Blind Period From the Baseline Value at the Start of the Open-Label Period</title>
          <description>Pain over the last 24 hours was assessed by using VAS score ranges from 0 mm=no pain to 100 mm=worst possible pain. An increase in score from Baseline represented disease progression and decrease represented improvement.</description>
          <population>Efficacy analysis set included participants who received at least one dose of study drug.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 of open-label period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.27" spread="13.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 1 of double-blind period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.17" spread="21.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the VAS24 Value From the Baseline at the Final Time Point of the Double-Blind Period</title>
        <description>Pain over the last 24 hours was assessed by using VAS score ranges from 0 mm=no pain to 100 mm=worst possible pain. An increase in score from Baseline represented disease progression and decrease represented improvement.</description>
        <time_frame>Day 1 and Day 28 of double-blind period</time_frame>
        <population>Efficacy analysis set included participants who received at least one dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride and Acetaminophen (Double-Blind)</title>
            <description>Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose [number of tablets] as that for the second week in the open-label period) was given 4 times daily up to 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Double-Blind)</title>
            <description>Matching placebo was given up to 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the VAS24 Value From the Baseline at the Final Time Point of the Double-Blind Period</title>
          <description>Pain over the last 24 hours was assessed by using VAS score ranges from 0 mm=no pain to 100 mm=worst possible pain. An increase in score from Baseline represented disease progression and decrease represented improvement.</description>
          <population>Efficacy analysis set included participants who received at least one dose of the study drug.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.33" spread="17.47"/>
                    <measurement group_id="O2" value="31.18" spread="16.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.67" spread="18.14"/>
                    <measurement group_id="O2" value="6.21" spread="22.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pain Intensity (PI) Score During Open-Label Period</title>
        <description>PI was evaluated on a 4-stage scale with a score ranging from 0 to 3, wherein 0=no pain and 3=severe pain.</description>
        <time_frame>Pre-dose and post-dose at 2 hours, 4 hours on Day 1, and Day 8 of open-label period</time_frame>
        <population>Efficacy analysis set included participants who received at least one dose of study drug. Here 'n' signifies number of participants evaluable for this outcome measure at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride and Acetaminophen (Open-Label)</title>
            <description>Fixed dose combination of tramadol 37.5 milligram (mg)/acetaminophen 325 mg, 1 or 2 tablets 4 times daily was given for one week; dose level was fixed for each participant during the second week based on analgesic efficacy and tolerability (maximum daily dose was 8 tablets).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Intensity (PI) Score During Open-Label Period</title>
          <description>PI was evaluated on a 4-stage scale with a score ranging from 0 to 3, wherein 0=no pain and 3=severe pain.</description>
          <population>Efficacy analysis set included participants who received at least one dose of study drug. Here 'n' signifies number of participants evaluable for this outcome measure at each time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; Pre-dose (n=275)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 2 hours after dosing (n=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 4 hours after dosing (n=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8; Pre-dose (n=219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8; 2 hours after dosing (n=219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8; 4 hours after dosing (n=219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean PI Score During Double-Blind Period</title>
        <description>The PI was evaluated on a 4-stage scale with a score ranging from 0 to 3, wherein 0=no pain and 3=severe pain.</description>
        <time_frame>Pre-dose and post-dose at 2 hours, 4 hours on Day 1, 8, 15, 22 and 28 of double-blind period</time_frame>
        <population>Efficacy analysis set included participants who received at least one dose of the study drug. Here 'n' signifies number of participants evaluable at each time point for each arm respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride and Acetaminophen (Double-Blind)</title>
            <description>Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose [number of tablets] as that for the second week in the open-label period) was given 4 times daily up to 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Double-Blind)</title>
            <description>Matching placebo was given up to 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean PI Score During Double-Blind Period</title>
          <description>The PI was evaluated on a 4-stage scale with a score ranging from 0 to 3, wherein 0=no pain and 3=severe pain.</description>
          <population>Efficacy analysis set included participants who received at least one dose of the study drug. Here 'n' signifies number of participants evaluable at each time point for each arm respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; Pre-dose (n=84, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.37"/>
                    <measurement group_id="O2" value="1.2" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 2 hours after dosing (n=84, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.44"/>
                    <measurement group_id="O2" value="1.1" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 4 hours after dosing (n=84, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.49"/>
                    <measurement group_id="O2" value="1.1" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8; Pre-dose (n=74, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.39"/>
                    <measurement group_id="O2" value="1.2" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8; 2 hours after dosing (n=74, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.47"/>
                    <measurement group_id="O2" value="1.1" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8; 4 hours after dosing (n=74, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.51"/>
                    <measurement group_id="O2" value="1.1" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15; Pre-dose (n=67, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.33"/>
                    <measurement group_id="O2" value="1.1" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15; 2 hours after dosing (n=67, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.46"/>
                    <measurement group_id="O2" value="1.0" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15; 4 hours after dosing (n=67, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.51"/>
                    <measurement group_id="O2" value="0.9" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22; Pre-dose (n=63, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.30"/>
                    <measurement group_id="O2" value="1.2" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22, 2 hours after dosing (n=63, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.42"/>
                    <measurement group_id="O2" value="1.0" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22; 4 hours after dosing (n=63, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.49"/>
                    <measurement group_id="O2" value="1.0" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28; Pre-dose (n=72, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.33"/>
                    <measurement group_id="O2" value="1.2" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28; 2 hours after dosing (n=72, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.44"/>
                    <measurement group_id="O2" value="1.0" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28; 4 hours after dosing (n=72, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.50"/>
                    <measurement group_id="O2" value="1.0" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pain Intensity Difference (PID) During the Open-Label Period</title>
        <description>The PID was calculated as PI at pre-dose on Day 1, 8 minus PI at post-dose time point (i.e., 2 hours and 4 hours) on Day 1, 8 respectively. Baseline PI score ranges from 1=minor to 3=severe, post-baseline PI score ranges from 0=none to 3=severe. Total possible score range for PID: -2=worst to 3=best.</description>
        <time_frame>Pre-dose, and post-dose at 2 hours, 4 hours on Day 1, and Day 8 of open-label period</time_frame>
        <population>Efficacy analysis set included participants who received at least one dose of study drug. Here 'n' signifies number of participants evaluable for this outcome measure at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride and Acetaminophen (Open-Label)</title>
            <description>Fixed dose combination of tramadol 37.5 milligram (mg)/acetaminophen 325 mg, 1 or 2 tablets 4 times daily was given for one week; dose level was fixed for each participant during the second week based on analgesic efficacy and tolerability (maximum daily dose was 8 tablets).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Intensity Difference (PID) During the Open-Label Period</title>
          <description>The PID was calculated as PI at pre-dose on Day 1, 8 minus PI at post-dose time point (i.e., 2 hours and 4 hours) on Day 1, 8 respectively. Baseline PI score ranges from 1=minor to 3=severe, post-baseline PI score ranges from 0=none to 3=severe. Total possible score range for PID: -2=worst to 3=best.</description>
          <population>Efficacy analysis set included participants who received at least one dose of study drug. Here 'n' signifies number of participants evaluable for this outcome measure at each time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; 2 hours after dosing (n=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 4 hours after dosing (n=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8; 2 hours after dosing (n=219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8; 4 hours after dosing (n=219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean PID During the Double-Blind Period</title>
        <description>The PID was calculated as PI at pre-dose on Day 1, 8, 15, 22, 28 minus PI at post-dose time point (i.e., 2 hours and 4 hours) on Day 1, 8, 15, 22, 28 respectively. Baseline PI score ranges from 1=minor to 3=severe, post-baseline PI score ranges from 0=none to 3=severe. Total possible score range for PID: -2=worst to 3=best.</description>
        <time_frame>Pre-dose, and post-dose at 2 hours, 4 hours on Day 1, 8, 15, 22 and 28 of double-blind period</time_frame>
        <population>Efficacy analysis set included participants received at least one dose of the study drug. Here 'n' signifies number of participants evaluable at each time point for each arm respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride and Acetaminophen (Double-Blind)</title>
            <description>Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose [number of tablets] as that for the second week in the open-label period) was given 4 times daily up to 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Double-Blind)</title>
            <description>Matching placebo was given up to 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean PID During the Double-Blind Period</title>
          <description>The PID was calculated as PI at pre-dose on Day 1, 8, 15, 22, 28 minus PI at post-dose time point (i.e., 2 hours and 4 hours) on Day 1, 8, 15, 22, 28 respectively. Baseline PI score ranges from 1=minor to 3=severe, post-baseline PI score ranges from 0=none to 3=severe. Total possible score range for PID: -2=worst to 3=best.</description>
          <population>Efficacy analysis set included participants received at least one dose of the study drug. Here 'n' signifies number of participants evaluable at each time point for each arm respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; 2 hours after dosing (n=84, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.40"/>
                    <measurement group_id="O2" value="0.1" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 4 hours after dosing (n=84, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.49"/>
                    <measurement group_id="O2" value="0.1" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8; 2 hours after dosing (n=74, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.39"/>
                    <measurement group_id="O2" value="0.1" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8; 4 hours after dosing (n=74, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.50"/>
                    <measurement group_id="O2" value="0.2" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15; 2 hours after dosing (n=67, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.36"/>
                    <measurement group_id="O2" value="0.2" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15; 4 hours after dosing (n=67, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.49"/>
                    <measurement group_id="O2" value="0.2" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22; 2 hours after dosing (n=63, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.35"/>
                    <measurement group_id="O2" value="0.2" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22; 4 hours after dosing (n=63, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.42"/>
                    <measurement group_id="O2" value="0.2" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28; 2 hours after dosing (n=72, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.36"/>
                    <measurement group_id="O2" value="0.2" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28; 4 hours after dosing (n=72, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.44"/>
                    <measurement group_id="O2" value="0.2" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pain Relief (PAR) Score During the Open-Label Period</title>
        <description>PAR was evaluated based on 5-stage scale with a score ranging from 0 to 4, wherein, 0=no relief and 4=complete relief.</description>
        <time_frame>2 hours, 4 hours post-dose on Day 1, and Day 8 of open-label period</time_frame>
        <population>Efficacy analysis set included participants who received at least one dose of study drug. Here 'n' signifies number of participants evaluable for this outcome measure at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride and Acetaminophen (Open-Label)</title>
            <description>Fixed dose combination of tramadol 37.5 milligram (mg)/acetaminophen 325 mg, 1 or 2 tablets 4 times daily was given for one week; dose level was fixed for each participant during the second week based on analgesic efficacy and tolerability (maximum daily dose was 8 tablets).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Relief (PAR) Score During the Open-Label Period</title>
          <description>PAR was evaluated based on 5-stage scale with a score ranging from 0 to 4, wherein, 0=no relief and 4=complete relief.</description>
          <population>Efficacy analysis set included participants who received at least one dose of study drug. Here 'n' signifies number of participants evaluable for this outcome measure at each time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; 2 hours after dosing (n=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 4 hours after dosing (n=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8; 2 hours after dosing (n=219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8; 4 hours after dosing (n=219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean PAR Score During the Double-Blind Period</title>
        <description>PAR was evaluated based on 5-stage scale with a score ranging from 0 to 4, wherein, 0=no relief and 4=complete relief.</description>
        <time_frame>2 hours, 4 hours post-dose on Day 1, 8, 15, 22 and 28 of double-blind period</time_frame>
        <population>Efficacy analysis set included participants received at least one dose of the study drug. Here 'n' signifies number of participants evaluable at each time point for each arm respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride and Acetaminophen (Double-Blind)</title>
            <description>Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose [number of tablets] as that for the second week in the open-label period) was given 4 times daily up to 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Double-Blind)</title>
            <description>Matching placebo was given up to 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean PAR Score During the Double-Blind Period</title>
          <description>PAR was evaluated based on 5-stage scale with a score ranging from 0 to 4, wherein, 0=no relief and 4=complete relief.</description>
          <population>Efficacy analysis set included participants received at least one dose of the study drug. Here 'n' signifies number of participants evaluable at each time point for each arm respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; 2 hours after dosing (n=84, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.02"/>
                    <measurement group_id="O2" value="1.1" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 4 hours after dosing (n=84, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.01"/>
                    <measurement group_id="O2" value="1.2" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8; 2 hours after dosing (n=74, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="1.06"/>
                    <measurement group_id="O2" value="1.2" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8; 4 hours after dosing (n=74, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="1.01"/>
                    <measurement group_id="O2" value="1.4" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15; 2 hours after dosing (n=67, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.09"/>
                    <measurement group_id="O2" value="1.7" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15; 4 hours after dosing (n=67, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.00"/>
                    <measurement group_id="O2" value="1.7" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22; 2 hours after dosing (n=63, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.96"/>
                    <measurement group_id="O2" value="1.8" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22; 4 hours after dosing (n=63, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="1.00"/>
                    <measurement group_id="O2" value="1.8" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28; 2 hours after dosing (n=72, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.00"/>
                    <measurement group_id="O2" value="1.6" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28; 4 hours after dosing (n=72, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.04"/>
                    <measurement group_id="O2" value="1.7" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Difference and Pain Relief Scores (PRID) During the Open-Label Period</title>
        <description>The PRID is defined as sum of PID and PAR Scores for each participant at each evaluation time point (at 2 and 4 hours after the dosing). The overall possible score ranges for PRID is -2=worst to 7=best. The PID was calculated as PI at pre-dose on Day 1, 8 minus PI at post-dose time point (i.e., 2 hours and 4 hours) on Day 1, 8 respectively. Baseline PI score ranges from 1=minor to 3=severe, post-baseline PI score ranges from 0=none to 3=severe. Total possible score range for PID: -2=worst to 3=best and PAR was evaluated based on a 5-stage scale score ranges from 0=no relief and 4=complete relief.</description>
        <time_frame>2 hours, 4 hours post-dose on Day 1, and Day 8 of open-label period</time_frame>
        <population>Efficacy analysis set included who received at least one dose of study medication. Here 'n' signifies number of participants evaluable for each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride and Acetaminophen (Open-Label)</title>
            <description>Fixed dose combination of tramadol 37.5 milligram (mg)/acetaminophen 325 mg, 1 or 2 tablets 4 times daily was given for one week; dose level was fixed for each participant during the second week based on analgesic efficacy and tolerability (maximum daily dose was 8 tablets).</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Difference and Pain Relief Scores (PRID) During the Open-Label Period</title>
          <description>The PRID is defined as sum of PID and PAR Scores for each participant at each evaluation time point (at 2 and 4 hours after the dosing). The overall possible score ranges for PRID is -2=worst to 7=best. The PID was calculated as PI at pre-dose on Day 1, 8 minus PI at post-dose time point (i.e., 2 hours and 4 hours) on Day 1, 8 respectively. Baseline PI score ranges from 1=minor to 3=severe, post-baseline PI score ranges from 0=none to 3=severe. Total possible score range for PID: -2=worst to 3=best and PAR was evaluated based on a 5-stage scale score ranges from 0=no relief and 4=complete relief.</description>
          <population>Efficacy analysis set included who received at least one dose of study medication. Here 'n' signifies number of participants evaluable for each time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; 2 hours after dosing (n=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 4 hours after dosing (n=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8; 2 hours after dosing (n=219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8; 4 hours after dosing (n=219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Difference and Pain Relief Scores (PRID) During the Double-Blind Period</title>
        <description>The PRID is defined as sum of PID and PAR Scores for each participant at each evaluation time point (at 2 and 4 hours after the dosing). The overall possible score range for PRID is -2=worst to 7=best. The PID was calculated as PI at pre-dose on Day 1, 8, 15, 22, 28 minus PI at post-dose time point (i.e., 2 hours and 4 hours) on Day 1, 8, 15, 22, 28 respectively. Baseline PI score ranges from 1=minor to 3=severe, post-baseline PI score ranges from 0=none to 3=severe. Total possible score range for PID: -2=worst to 3=best and PAR was evaluated based on a 5-stage scale score ranges from 0=no relief and 4=complete relief.</description>
        <time_frame>2 hours, 4 hours post-dose on Day 1, 8, 15, 22 and 28 of double-blind period</time_frame>
        <population>Efficacy analysis set included participants received at least one dose of the study drug. Here 'n' signifies number of participants evaluable at each time point for each arm respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride and Acetaminophen (Double-Blind)</title>
            <description>Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose [number of tablets] as that for the second week in the open-label period) was given 4 times daily up to 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Double-Blind)</title>
            <description>Matching placebo was given up to 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Difference and Pain Relief Scores (PRID) During the Double-Blind Period</title>
          <description>The PRID is defined as sum of PID and PAR Scores for each participant at each evaluation time point (at 2 and 4 hours after the dosing). The overall possible score range for PRID is -2=worst to 7=best. The PID was calculated as PI at pre-dose on Day 1, 8, 15, 22, 28 minus PI at post-dose time point (i.e., 2 hours and 4 hours) on Day 1, 8, 15, 22, 28 respectively. Baseline PI score ranges from 1=minor to 3=severe, post-baseline PI score ranges from 0=none to 3=severe. Total possible score range for PID: -2=worst to 3=best and PAR was evaluated based on a 5-stage scale score ranges from 0=no relief and 4=complete relief.</description>
          <population>Efficacy analysis set included participants received at least one dose of the study drug. Here 'n' signifies number of participants evaluable at each time point for each arm respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; 2 hours after dosing (n=84, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="1.20"/>
                    <measurement group_id="O2" value="1.2" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; 4 hours after dosing (n=84, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.28"/>
                    <measurement group_id="O2" value="1.2" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8; 2 hours after dosing (n=74, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.23"/>
                    <measurement group_id="O2" value="1.4" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8; 4 hours after dosing (n=74, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.22"/>
                    <measurement group_id="O2" value="1.6" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15; 2 hours after dosing (n=67, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="1.29"/>
                    <measurement group_id="O2" value="1.8" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15; 4 hours after dosing (n=67, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="1.27"/>
                    <measurement group_id="O2" value="1.9" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22; 2 hours after dosing (n=63, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.10"/>
                    <measurement group_id="O2" value="2.0" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22; 4 hours after dosing (n=63, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="1.24"/>
                    <measurement group_id="O2" value="2.1" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28; 2 hours after dosing (n=72, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="1.14"/>
                    <measurement group_id="O2" value="1.8" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28; 4 hours after dosing (n=72, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="1.28"/>
                    <measurement group_id="O2" value="1.9" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sum of Pain Intensity Difference (SPID) Score During the Open-Label Period</title>
        <description>The SPID is defined as sum of the PID at 2 and 4 hours after dosing on each evaluation day. The overall possible score ranges for SPID is -4=worst to 6=best. The PID was calculated as PI at pre-dose on Day 1, 8 minus PI at post-dose time point (i.e., 2 hours and 4 hours) on Day 1, 8 respectively. Baseline PI score ranges from 1=minor to 3=severe, post-baseline PI score ranges from 0=none to 3=severe. Total possible score range for PID: -2=worst to 3=best.</description>
        <time_frame>Day 1, and Day 8 of open-label period</time_frame>
        <population>Efficacy analysis set included participants received at least one dose of the study drug. Here 'n' signifies number of participants evaluable for this outcome measure at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride and Acetaminophen (Open-Label)</title>
            <description>Fixed dose combination of tramadol 37.5 milligram (mg)/acetaminophen 325 mg, 1 or 2 tablets 4 times daily was given for one week; dose level was fixed for each participant during the second week based on analgesic efficacy and tolerability (maximum daily dose was 8 tablets).</description>
          </group>
        </group_list>
        <measure>
          <title>Sum of Pain Intensity Difference (SPID) Score During the Open-Label Period</title>
          <description>The SPID is defined as sum of the PID at 2 and 4 hours after dosing on each evaluation day. The overall possible score ranges for SPID is -4=worst to 6=best. The PID was calculated as PI at pre-dose on Day 1, 8 minus PI at post-dose time point (i.e., 2 hours and 4 hours) on Day 1, 8 respectively. Baseline PI score ranges from 1=minor to 3=severe, post-baseline PI score ranges from 0=none to 3=severe. Total possible score range for PID: -2=worst to 3=best.</description>
          <population>Efficacy analysis set included participants received at least one dose of the study drug. Here 'n' signifies number of participants evaluable for this outcome measure at each time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 (n=219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sum of Pain Intensity Difference (SPID) Score During the Double-Blind Period</title>
        <description>The SPID is defined as sum of the PID at 2 and 4 hours after dosing on each evaluation day. The overall possible score ranges for SPID is -4=worst to 6=best. The PID was calculated as PI at pre-dose on Day 1, 8, 15, 22, 28 minus PI at post-dose time point (i.e., 2 hours and 4 hours) on Day 1, 8, 15, 22, 28 respectively. Baseline PI score ranges from 1=minor to 3=severe, post-baseline PI score ranges from 0=none to 3=severe. Total possible score range for PID: -2=worst to 3=best.</description>
        <time_frame>Day 1, 8, 15, 22 and 28 of double-blind period</time_frame>
        <population>Efficacy analysis set included participants received at least one dose of the study drug. Here 'n' signifies number of participants evaluable at each time point for each arm respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride and Acetaminophen (Double-Blind)</title>
            <description>Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose [number of tablets] as that for the second week in the open-label period) was given 4 times daily up to 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Double-Blind)</title>
            <description>Matching placebo was given up to 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Sum of Pain Intensity Difference (SPID) Score During the Double-Blind Period</title>
          <description>The SPID is defined as sum of the PID at 2 and 4 hours after dosing on each evaluation day. The overall possible score ranges for SPID is -4=worst to 6=best. The PID was calculated as PI at pre-dose on Day 1, 8, 15, 22, 28 minus PI at post-dose time point (i.e., 2 hours and 4 hours) on Day 1, 8, 15, 22, 28 respectively. Baseline PI score ranges from 1=minor to 3=severe, post-baseline PI score ranges from 0=none to 3=severe. Total possible score range for PID: -2=worst to 3=best.</description>
          <population>Efficacy analysis set included participants received at least one dose of the study drug. Here 'n' signifies number of participants evaluable at each time point for each arm respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=84, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.79"/>
                    <measurement group_id="O2" value="0.1" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 (n=74, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.81"/>
                    <measurement group_id="O2" value="0.3" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (n=67, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.76"/>
                    <measurement group_id="O2" value="0.4" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 (n=63, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.73"/>
                    <measurement group_id="O2" value="0.5" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (n=72, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.74"/>
                    <measurement group_id="O2" value="0.4" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Pain Relief (TOTPAR) Score During the Open-Label Period</title>
        <description>The TOTPAR is defined as sum of PAR at 2 hours after dosing and the PAR at 4 hours after dosing on each evaluation day. Pain relief as evaluated on 5-stage scale with a score ranging from 0=no relief and 4=complete relief. Total possible score range for TOTPAR is 0=no relief to 8=complete relief.</description>
        <time_frame>Day 1 and Day 8 of open-label period</time_frame>
        <population>Efficacy analysis set included who received at least one dose of study drug. Here 'n' signifies number of participants evaluable for each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride and Acetaminophen (Open-Label)</title>
            <description>Fixed dose combination of tramadol 37.5 milligram (mg)/acetaminophen 325 mg, 1 or 2 tablets 4 times daily was given for one week; dose level was fixed for each participant during the second week based on analgesic efficacy and tolerability (maximum daily dose was 8 tablets).</description>
          </group>
        </group_list>
        <measure>
          <title>Total Pain Relief (TOTPAR) Score During the Open-Label Period</title>
          <description>The TOTPAR is defined as sum of PAR at 2 hours after dosing and the PAR at 4 hours after dosing on each evaluation day. Pain relief as evaluated on 5-stage scale with a score ranging from 0=no relief and 4=complete relief. Total possible score range for TOTPAR is 0=no relief to 8=complete relief.</description>
          <population>Efficacy analysis set included who received at least one dose of study drug. Here 'n' signifies number of participants evaluable for each time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 (n=219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Pain Relief (TOTPAR) Score During the Double-Blind Period</title>
        <description>The TOTPAR is defined as sum of PAR at 2 hours after dosing and the PAR at 4 hours after dosing on each evaluation day. Pain relief as evaluated on 5-stage scale with a score ranging from 0=no relief and 4=complete relief. Total possible score range for TOTPAR is 0=no relief to 8=complete relief.</description>
        <time_frame>Day 1, 8, 15, 22 and 28 of double-blind period</time_frame>
        <population>Efficacy analysis set included participants received at least one dose of the study drug. Here 'n' signifies number of participants evaluable at each time point for each arm respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride and Acetaminophen (Double-Blind)</title>
            <description>Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose [number of tablets] as that for the second week in the open-label period) was given 4 times daily up to 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Double-Blind)</title>
            <description>Matching placebo was given up to 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Pain Relief (TOTPAR) Score During the Double-Blind Period</title>
          <description>The TOTPAR is defined as sum of PAR at 2 hours after dosing and the PAR at 4 hours after dosing on each evaluation day. Pain relief as evaluated on 5-stage scale with a score ranging from 0=no relief and 4=complete relief. Total possible score range for TOTPAR is 0=no relief to 8=complete relief.</description>
          <population>Efficacy analysis set included participants received at least one dose of the study drug. Here 'n' signifies number of participants evaluable at each time point for each arm respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=84, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1.97"/>
                    <measurement group_id="O2" value="2.3" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 (n=74, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="2.00"/>
                    <measurement group_id="O2" value="2.6" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (n=67, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="2.04"/>
                    <measurement group_id="O2" value="3.3" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 (n=63, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="1.91"/>
                    <measurement group_id="O2" value="3.6" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (n=72, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="1.99"/>
                    <measurement group_id="O2" value="3.3" spread="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sum of Pain Relief Combined With Pain Intensity Difference (SPRID) Score During the Open-Label Period</title>
        <description>The SPRID is defined as sum of PID and PAR Scores at 2 hours and 4 hours after the dosing on each evaluation day. The overall possible score ranges for SPRID is -4=worst to 14=best. The PID was calculated as PI at pre-dose on Day 1, 8 minus PI at post-dose time point (i.e., 2 hours and 4 hours) on Day 1, 8 respectively. Baseline PI score ranges from 1=minor to 3=severe, post-baseline PI score ranges from 0=none to 3=severe. Total possible score range for PID: -2=worst to 3=best and PAR was evaluated based on 5-stage scale with a score ranging from 0=no relief to 4=complete relief.</description>
        <time_frame>Day 1, and Day 8 of open-label period</time_frame>
        <population>Efficacy analysis set included who received at least one dose of study drug. Here 'n' signifies number of participants evaluable for each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride and Acetaminophen (Open-Label)</title>
            <description>Fixed dose combination of tramadol 37.5 milligram (mg)/acetaminophen 325 mg, 1 or 2 tablets 4 times daily was given for one week; dose level was fixed for each participant during the second week based on analgesic efficacy and tolerability (maximum daily dose was 8 tablets).</description>
          </group>
        </group_list>
        <measure>
          <title>Sum of Pain Relief Combined With Pain Intensity Difference (SPRID) Score During the Open-Label Period</title>
          <description>The SPRID is defined as sum of PID and PAR Scores at 2 hours and 4 hours after the dosing on each evaluation day. The overall possible score ranges for SPRID is -4=worst to 14=best. The PID was calculated as PI at pre-dose on Day 1, 8 minus PI at post-dose time point (i.e., 2 hours and 4 hours) on Day 1, 8 respectively. Baseline PI score ranges from 1=minor to 3=severe, post-baseline PI score ranges from 0=none to 3=severe. Total possible score range for PID: -2=worst to 3=best and PAR was evaluated based on 5-stage scale with a score ranging from 0=no relief to 4=complete relief.</description>
          <population>Efficacy analysis set included who received at least one dose of study drug. Here 'n' signifies number of participants evaluable for each time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=274)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 (n=219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sum of Pain Relief Combined With Pain Intensity Difference (SPRID) Score During the Double-Blind Period</title>
        <description>The SPRID is defined as sum of PID and PAR Scores at 2 hours and 4 hours after the dosing on each evaluation day. The overall possible score ranges for SPRID is -4=worst to 14=best. The PID was calculated as PI at pre-dose on Day 1, 8, 15, 22, 28 minus PI at post-dose time point (i.e., 2 hours and 4 hours) on Day 1, 8, 15, 22, 28 respectively. Baseline PI score ranges from 1=minor to 3=severe, post-baseline PI score ranges from 0=none to 3=severe. Total possible score range for PID: -2=worst to 3=best and PAR was evaluated based on 5-stage scale with a score ranging from 0 to 4, wherein, 0=no relief and 4=complete relief.</description>
        <time_frame>Day 1, 8, 15, 22 and 28 of double-blind period</time_frame>
        <population>Efficacy analysis set included participants received at least one dose of the study drug. Here 'n' signifies number of participants evaluable at each time point for each arm respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride and Acetaminophen (Double-Blind)</title>
            <description>Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose [number of tablets] as that for the second week in the open-label period) was given 4 times daily up to 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Double-Blind)</title>
            <description>Matching placebo was given up to 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Sum of Pain Relief Combined With Pain Intensity Difference (SPRID) Score During the Double-Blind Period</title>
          <description>The SPRID is defined as sum of PID and PAR Scores at 2 hours and 4 hours after the dosing on each evaluation day. The overall possible score ranges for SPRID is -4=worst to 14=best. The PID was calculated as PI at pre-dose on Day 1, 8, 15, 22, 28 minus PI at post-dose time point (i.e., 2 hours and 4 hours) on Day 1, 8, 15, 22, 28 respectively. Baseline PI score ranges from 1=minor to 3=severe, post-baseline PI score ranges from 0=none to 3=severe. Total possible score range for PID: -2=worst to 3=best and PAR was evaluated based on 5-stage scale with a score ranging from 0 to 4, wherein, 0=no relief and 4=complete relief.</description>
          <population>Efficacy analysis set included participants received at least one dose of the study drug. Here 'n' signifies number of participants evaluable at each time point for each arm respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=84, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="2.37"/>
                    <measurement group_id="O2" value="2.4" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 (n=74, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="2.32"/>
                    <measurement group_id="O2" value="3.0" spread="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (n=67, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="2.46"/>
                    <measurement group_id="O2" value="3.7" spread="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 (n=63, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="2.27"/>
                    <measurement group_id="O2" value="4.0" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (n=72, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="2.35"/>
                    <measurement group_id="O2" value="3.7" spread="2.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Roland Morris Disability Questionnaire (RDQ) Total Score at Day 14 of Open-Label Period</title>
        <description>The RDQ is self-administered measure of disability caused by low back pain and consists of 24 statements. The total score ranges from 0=no disability to 24=severe disability. The higher scores indicate greater physical disability.</description>
        <time_frame>Day 1 and Day 14 of open-label period</time_frame>
        <population>Efficacy analysis set included who received at least one dose of study drug and had the lumbago as the target disease. Here 'n' signifies number of participants evaluable for this outcome measure at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride and Acetaminophen (Open-Label)</title>
            <description>Fixed dose combination of tramadol 37.5 milligram (mg)/acetaminophen 325 mg, 1 or 2 tablets 4 times daily was given for one week; dose level was fixed for each participant during the second week based on analgesic efficacy and tolerability (maximum daily dose was 8 tablets).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Roland Morris Disability Questionnaire (RDQ) Total Score at Day 14 of Open-Label Period</title>
          <description>The RDQ is self-administered measure of disability caused by low back pain and consists of 24 statements. The total score ranges from 0=no disability to 24=severe disability. The higher scores indicate greater physical disability.</description>
          <population>Efficacy analysis set included who received at least one dose of study drug and had the lumbago as the target disease. Here 'n' signifies number of participants evaluable for this outcome measure at each time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="4.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 14 (n=126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="3.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in RDQ Total Score at Day 28 of Double-Blind Period</title>
        <description>The RDQ is self-administered measure of disability caused by low back pain and consists of 24 statements. The total score ranges from 0=no disability to 24=severe disability. The higher scores indicate greater physical disability.</description>
        <time_frame>Day 1 and Day 28 of double-blind period</time_frame>
        <population>Efficacy analysis set included participants received at least one dose of the study drug and had the lumbago as the target disease. Here 'n' signifies number of participants evaluable at each time point for each arm respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride and Acetaminophen (Double-Blind)</title>
            <description>Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose [number of tablets] as that for the second week in the open-label period) was given 4 times daily up to 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Double-Blind)</title>
            <description>Matching placebo was given up to 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in RDQ Total Score at Day 28 of Double-Blind Period</title>
          <description>The RDQ is self-administered measure of disability caused by low back pain and consists of 24 statements. The total score ranges from 0=no disability to 24=severe disability. The higher scores indicate greater physical disability.</description>
          <population>Efficacy analysis set included participants received at least one dose of the study drug and had the lumbago as the target disease. Here 'n' signifies number of participants evaluable at each time point for each arm respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=55, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="4.41"/>
                    <measurement group_id="O2" value="6.0" spread="4.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28 (n=55, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="3.08"/>
                    <measurement group_id="O2" value="0.8" spread="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Questionnaire Score at Day 14 of Open-Label Period</title>
        <description>The WOMAC questionnaire is an activity of daily living (ADL) indicator for Knee Osteoarthritis and designed to capture the elements of pain, stiffness, extent of obstruction to daily activities (EODA) and general index. The score for each element ranges from 0=better ADL to 10=worse ADL.</description>
        <time_frame>Day 1 and Day 14 of open-label period</time_frame>
        <population>Efficacy analysis set included who received at least one dose of study drug and had the knee osteoarthritis as the target disease. Here 'n' signifies number of participants evaluable for this outcome measure at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride and Acetaminophen (Open-Label)</title>
            <description>Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose [number of tablets] as that for the second week in the open-label period) was given 4 times daily up to 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Questionnaire Score at Day 14 of Open-Label Period</title>
          <description>The WOMAC questionnaire is an activity of daily living (ADL) indicator for Knee Osteoarthritis and designed to capture the elements of pain, stiffness, extent of obstruction to daily activities (EODA) and general index. The score for each element ranges from 0=better ADL to 10=worse ADL.</description>
          <population>Efficacy analysis set included who received at least one dose of study drug and had the knee osteoarthritis as the target disease. Here 'n' signifies number of participants evaluable for this outcome measure at each time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; Pain (n=117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 14; Pain (n=90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; Stiffness (n=117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 14; Stiffness (n=90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; EODA (n=117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 14; EODA (n=90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; General index (n=117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 14; General index (n=90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in WOMAC Questionnaire Score at Day 28 of Double-Blind Period</title>
        <description>The WOMAC questionnaire is an activity of daily living (ADL) indicator for knee osteoarthritis and designed to capture the elements of pain, stiffness, extent of obstruction to daily activities (EODA) and general index. The score for each element ranges from 0=better ADL to 10=worse ADL.</description>
        <time_frame>Day 1 and Day 28 of double-blind period</time_frame>
        <population>Efficacy analysis set included who received at least one dose of study drug and had the knee osteoarthritis as the target disease. Here 'n' signifies number of participants evaluable at each time point for each arm respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride and Acetaminophen (Double-Blind)</title>
            <description>Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose [number of tablets] as that for the second week in the open-label period) was given 4 times daily up to 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Double-Blind)</title>
            <description>Matching placebo was given up to 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WOMAC Questionnaire Score at Day 28 of Double-Blind Period</title>
          <description>The WOMAC questionnaire is an activity of daily living (ADL) indicator for knee osteoarthritis and designed to capture the elements of pain, stiffness, extent of obstruction to daily activities (EODA) and general index. The score for each element ranges from 0=better ADL to 10=worse ADL.</description>
          <population>Efficacy analysis set included who received at least one dose of study drug and had the knee osteoarthritis as the target disease. Here 'n' signifies number of participants evaluable at each time point for each arm respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; Pain (n=39, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="1.46"/>
                    <measurement group_id="O2" value="2.2" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28; Pain (n=39, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.02"/>
                    <measurement group_id="O2" value="0.5" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; Stiffness (n=39, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="1.94"/>
                    <measurement group_id="O2" value="2.4" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28; Stiffness (n=39, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.33"/>
                    <measurement group_id="O2" value="0.2" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; EODA (n=39, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.68"/>
                    <measurement group_id="O2" value="1.9" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28; EODA (n=39, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.58"/>
                    <measurement group_id="O2" value="0.4" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; General index (n=39, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="1.48"/>
                    <measurement group_id="O2" value="2.2" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28; General index (n=39, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.65"/>
                    <measurement group_id="O2" value="0.4" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short Form-36 (SF-36) Score at Day 14 of Open-Label Period</title>
        <description>The SF-36 is a survey of participant health and quality of life. It consists of 8 sub-scales, which are the weighted sums of the questions in their section. The 8 sub-scales are: physical functioning, role-physical, role-emotional, general health, social functioning, bodily pain, vitality, mental health. Each item is scored on a scale ranging from 0-100. Higher score defines a more favorable health status or a better mental status.</description>
        <time_frame>Day 1 and Day 14 of open-label period</time_frame>
        <population>Efficacy analysis set included who received at least one dose of study drug. Here 'n' signifies number of participants evaluable for this outcome measure at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride and Acetaminophen (Open-Label)</title>
            <description>Fixed dose combination of tramadol 37.5 milligram (mg)/acetaminophen 325 mg, 1 or 2 tablets 4 times daily was given for one week; dose level was fixed for each participant during the second week based on analgesic efficacy and tolerability (maximum daily dose was 8 tablets).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short Form-36 (SF-36) Score at Day 14 of Open-Label Period</title>
          <description>The SF-36 is a survey of participant health and quality of life. It consists of 8 sub-scales, which are the weighted sums of the questions in their section. The 8 sub-scales are: physical functioning, role-physical, role-emotional, general health, social functioning, bodily pain, vitality, mental health. Each item is scored on a scale ranging from 0-100. Higher score defines a more favorable health status or a better mental status.</description>
          <population>Efficacy analysis set included who received at least one dose of study drug. Here 'n' signifies number of participants evaluable for this outcome measure at each time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; Physical functioning (n=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.3" spread="15.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 14; Physical functioning (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="10.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; Role-physical (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0" spread="13.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 14; Role-physical (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="11.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; Bodily pain (n=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8" spread="6.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 14; Bodily pain (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="7.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; General health (n=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.4" spread="9.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 14; General health (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="6.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; Vitality (n=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1" spread="9.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 14; Vitality (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="8.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; Social functioning (n=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.5" spread="12.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 14; Social functioning (n=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="10.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; Role-emotional (n=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2" spread="12.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 14; Role-emotional (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="11.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; Mental health (n=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.8" spread="9.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 14; Mental health (n=216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="8.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SF-36 at Day 28 of Double-Blind Period</title>
        <description>The SF-36 is a survey of participant health and quality of life. It consists of 8 sub-scales, which are the weighted sums of the questions in their section. The 8 sub-scales are: physical functioning, role-physical, role-emotional, general health, social functioning, bodily pain, vitality, mental health. Each item is scored on a scale ranging from 0-100. Higher score defines a more favorable health status or a better mental status.</description>
        <time_frame>Day 1 and Day 28 of double-blind period</time_frame>
        <population>Efficacy analysis set included participants received at least one dose of the study drug. Here 'n' signifies number of participants evaluable at each time point for each arm respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride and Acetaminophen (Double-Blind)</title>
            <description>Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose [number of tablets] as that for the second week in the open-label period) was given 4 times daily up to 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Double-Blind)</title>
            <description>Matching placebo was given up to 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SF-36 at Day 28 of Double-Blind Period</title>
          <description>The SF-36 is a survey of participant health and quality of life. It consists of 8 sub-scales, which are the weighted sums of the questions in their section. The 8 sub-scales are: physical functioning, role-physical, role-emotional, general health, social functioning, bodily pain, vitality, mental health. Each item is scored on a scale ranging from 0-100. Higher score defines a more favorable health status or a better mental status.</description>
          <population>Efficacy analysis set included participants received at least one dose of the study drug. Here 'n' signifies number of participants evaluable at each time point for each arm respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1; Physical functioning (n=94,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0" spread="12.28"/>
                    <measurement group_id="O2" value="39.7" spread="13.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28; Physical functioning (n=94,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="8.49"/>
                    <measurement group_id="O2" value="-1.6" spread="10.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; Role-physical (n=94,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5" spread="12.84"/>
                    <measurement group_id="O2" value="41.8" spread="12.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28; Role-physical (n=94,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="11.87"/>
                    <measurement group_id="O2" value="-0.6" spread="9.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; Bodily pain (n=94,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0" spread="7.68"/>
                    <measurement group_id="O2" value="39.3" spread="7.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28; Bodily pain (n=94,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="7.24"/>
                    <measurement group_id="O2" value="0.3" spread="7.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; General health (n=94,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.1" spread="9.23"/>
                    <measurement group_id="O2" value="48.0" spread="9.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28; General health (n=94,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="7.11"/>
                    <measurement group_id="O2" value="-1.2" spread="5.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; Vitality (n=94,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3" spread="9.58"/>
                    <measurement group_id="O2" value="47.4" spread="8.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28; Vitality (n=94,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="7.40"/>
                    <measurement group_id="O2" value="0.1" spread="7.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; Social functioning (n=94,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.4" spread="12.68"/>
                    <measurement group_id="O2" value="45.7" spread="11.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28; Social functioning (n=94,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="11.32"/>
                    <measurement group_id="O2" value="0.4" spread="10.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; Role-emotional (n=94,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7" spread="11.46"/>
                    <measurement group_id="O2" value="45.8" spread="11.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28; Role-emotional (n=94,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="9.49"/>
                    <measurement group_id="O2" value="-1.0" spread="9.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1; Mental health (n=94,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.4" spread="9.14"/>
                    <measurement group_id="O2" value="49.6" spread="8.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28; Mental health (n=94,93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="7.29"/>
                    <measurement group_id="O2" value="-0.7" spread="8.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the start of open-label period until 7 days after the last dose of study medication</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tramadol Hydrochloride and Acetaminophen (Open-Label)</title>
          <description>Fixed dose combination of tramadol 37.5 milligram (mg)/acetaminophen 325 mg, 1 or 2 tablets 4 times daily was given for one week; dose level was fixed for each participant during the second week based on analgesic efficacy and tolerability (maximum daily dose was 8 tablets).</description>
        </group>
        <group group_id="E2">
          <title>Tramadol Hydrochloride and Acetaminophen (Double-Blind)</title>
          <description>Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose [number of tablets] as that for the second week in the open-label period) was given 4 times daily up to 4 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Placebo (Double-Blind)</title>
          <description>Matching placebo was given up to 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA/J V11.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA/J V11.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="222" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Menieres disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Rotatory vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal sensation in the eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Vision impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Gastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Upper abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Indigestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Abnormal gastrointestinal sounds</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Glossitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal sensation</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Lassitude</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver function abnormality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Sty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall/tumble</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Neck injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>-glutamyl transferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Blood pressure elevated</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Urine glucose positive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Urine blood positive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Blood creatinine decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Eosinophil fraction increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Neutrophil fraction increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Lymphocyte fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Urine protein positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Blood K increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Lipids increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Liver function test abnormality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Kidney function test abnormality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Leg mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Attention deficit</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Hypoesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Tremors</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Positional vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Convulsions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Urination disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Ischuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Upper respiratory inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Excessive perspiration</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Exanthema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Allergic pruritus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Ingrown nail</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Systemic pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Heat rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Blushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PIs is that the Sponsor can review results communications prior to public release.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Neuroscience Department, Clinical Science Division, R&amp;D, JANSSEN PHARMACEUTICAL. K.K.</organization>
      <phone>+81-3-4411-5509</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

